Lorus Therapeutics Inc. (Lorus) is a biopharmaceutical company. The Company is a discovery, research and clinical development-stage company with a focus on cancer drugs. The Company has an active portfolio, including small molecules (LOR-253/LOR-500) and an immunotherapy (IL-17E). Lorus has worked to establish a marketable anticancer product pipeline, with products in various stages of development ranging from discovery and pre-clinical to a product available to start a Phase III clinical trial. Lorus has one subsidiary, NuChem Pharmaceuticals Inc. (NuChem).